Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE

OBJECTIVE: Anifrolumab is a fully human immunoglobulin G(1) κ monoclonal antibody specific for subunit 1 of the type I interferon (IFN) α receptor. In a phase IIb study of adults with moderate to severe SLE, anifrolumab treatment demonstrated substantial reductions in multiple clinical endpoints. He...

Descripción completa

Detalles Bibliográficos
Autores principales: Casey, Kerry A, Guo, Xiang, Smith, Michael A, Wang, Shiliang, Sinibaldi, Dominic, Sanjuan, Miguel A, Wang, Liangwei, Illei, Gabor G, White, Wendy I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Biomarker Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257383/
https://www.ncbi.nlm.nih.gov/pubmed/30538817
http://dx.doi.org/10.1136/lupus-2018-000286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257383/
https://www.ncbi.nlm.nih.gov/pubmed/30538817
http://dx.doi.org/10.1136/lupus-2018-000286

Ejemplares similares